ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Aiming to add gene and cell therapy to its drug contract development and manufacturing business, the Japanese glass and chemical firm AGC is buying MolMed, a clinical-stage biotech services firm, for about $260 million. Based in Milan, MolMed specializes in viral vectors and cell engineering. AGC acquired Malgrat Pharma Chemical, a Spanish maker of pharmaceutical chemicals, from Boehringer Ingelheim in 2018. AGC targets annual sales of about $900 million for its drug services business by 2025.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter